Annotation | Therapy type |
---|---|
A | 131I-NaI for benign thyroid diseases |
B | 131I-NaI for thyroid remnant ablation of adults |
C | 131I-NaI for thyroid remnant ablation of children and young adults |
D | 131I-NaI for thyroid cancer therapy for adults |
E | 131I-NaI for thyroid cancer therapy for children and young adults |
F | 131I-mIBG for neuroblastoma |
G | 131I-mIBG for adult neuroendocrine tumors |
H | 177Lu-somatostatin analogues for neuroendocrine tumors |
I | 90Y-somatostatin analogues for neuroendocrine tumors |
J | 177Lu-PSMA therapy of castration resistant prostate cancer |
K | 90Y resin microspheres (SIR-Spheres®) for intra-arterial treatments in the liver |
L | 90Y glass microspheres (TheraSphere®) for intra-arterial treatments in the liver |
M | Radiation synovectomy using 90Y-, 186Re-, or 169Er-colloids |
N | 153Sm-EDTMP (Quadramet®) for bone metastases |
O | 89SrCl2 (Metastron®) for bone metastases |
P | 223RaCl2 (Xofigo®) for bone metastases |
Q | 32P sodium-phosphate (Na3 32PO4) for myeloproliferative disease |
R | 90Y-ibritumomab-tiuxetan (Zevalin®) for B-cell lymphoma |
S–U | Therapy using alpha emitting radionuclides other than 223Ra |
V–X | Therapy using other radiopharmaceutical |